<SEC-DOCUMENT>0001193125-22-142918.txt : 20220506
<SEC-HEADER>0001193125-22-142918.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220506064253
ACCESSION NUMBER:		0001193125-22-142918
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220506
FILED AS OF DATE:		20220506
DATE AS OF CHANGE:		20220506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		22898760

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KONINKLIJKE PHILIPS ELECTRONICS NV
		DATE OF NAME CHANGE:	19981217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d322054d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or <FONT STYLE="white-space:nowrap">15d-16</FONT> of
the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;6, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File No.: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">001-05146-01</FONT></FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>KONINKLIJKE PHILIPS N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Royal Philips </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Jurisdiction of incorporation or organization) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Breitner
Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule101(b)(7):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d322054dex991.htm">Press release issued by Koninklijke Philips N.V. (the &#147;Company&#148;) on May&nbsp;5, 2022 announcing the pricing terms of any and all tender offer for certain outstanding <FONT
STYLE="white-space:nowrap">USD-denominated</FONT> notes. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d322054dex992.htm">Press release issued by the Company on May&nbsp;6, 2022 announcing the results of any and all tender offer for certain outstanding <FONT STYLE="white-space:nowrap">USD-denominated</FONT> notes.
</A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the
undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">KONINKLIJKE PHILIPS N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;6, 2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;/s/ M.J. van Ginneken</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M.J. van Ginneken</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Legal Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d322054dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR
DISTRIBUTION IS UNLAWFUL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May&nbsp;5, 2022 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Koninklijke Philips N.V. Announces Pricing Terms of Any and All Tender Offer for Certain Outstanding
<FONT STYLE="white-space:nowrap">USD-Denominated</FONT> Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amsterdam, The Netherlands </B>&#150; Koninklijke Philips N.V. (&#147;<B>Royal
Philips</B>&#148; or the &#147;<B>Company</B>&#148;) today announces the pricing terms of its previously announced tender offer (the &#147;<B>Offer</B>&#148;) to purchase for cash any and all of its outstanding 7<SUP
STYLE="font-size:85%; vertical-align:top">1/8</SUP>% Series A Debentures due 2025 (the &#147;<B>2025 Series A Notes</B>&#148;), 7<SUP STYLE="font-size:85%; vertical-align:top">3/4</SUP>% Series B Debentures due 2025 (the &#147;<B>2025 Series B
Notes</B>&#148;) and 7.200% Notes due 2026 (the &#147;<B>2026 Notes</B>&#148; and, together with the 2025 Series A Notes and the 2025 Series B Notes, the &#147;<B>Notes</B>&#148;). The Offer is being made in accordance with the terms and subject to
the conditions set forth in the Offer to Purchase, dated April&nbsp;28, 2022 (the &#147;<B>Offer to Purchase</B>&#148;) and the related Notice of Guaranteed Delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final deadline for holders to tender Notes to be eligible to receive the applicable Consideration (as defined below) is 5:00 p.m., New York City time, on
May&nbsp;5, 2022, unless extended with respect to any or all series of Notes (the &#147;<B>Expiration Time</B>&#148;). Holders of Notes validly tendered and not validly withdrawn at or before the Expiration Time and accepted for purchase will
receive the Consideration for such Notes. Tendered Notes may be withdrawn at any time at or before 5:00 p.m., New York City time, on May&nbsp;5, 2022, unless extended with respect to any or all series of Notes (such date and time, as the same may be
extended, the &#147;<B>Withdrawal Deadline</B>&#148;), but not thereafter. Subject to applicable law, the Company expressly reserves the right to terminate, in its sole discretion, the Offer at any time at or before the Expiration Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders who tender their Notes pursuant to the Guaranteed Delivery Procedures set out in the Offer to Purchase must ensure that the Eligible Guarantor
Institution (as defined in the Offer to Purchase) will procure that DTC properly transmits an Agent&#146;s Message (as defined in the Offer to Purchase) (together with the related book-entry delivery of the relevant Notes and any other documents
required) to the Tender and Information Agent by no later than 5:00 p.m., New York City time) on May&nbsp;9, 2022, the second business day after the date of the Expiration Time (the &#147;<B>Guaranteed Delivery Deadline</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable &#147;<B>Consideration</B>&#148; for Notes accepted for purchase pursuant to the Offer has been determined as described in the Offer to
Purchase in a manner intended to result in a yield to maturity, with reference to the Settlement Date (as defined below), equal to the sum of the applicable fixed spread specified in the table below (the &#147;<B>Fixed Spread</B>&#148;) for such
Notes and the yield based on the <FONT STYLE="white-space:nowrap">bid-side</FONT> price of the applicable U.S. Treasury Security specified in the table below (the &#147;<B>Reference Yield</B>&#148;) for such Notes. The Reference Yield for each
series of Notes was determined at 10:00 a.m., New York City time, today, May&nbsp;5, 2022 (the &#147;<B>Price Determination Time</B>&#148;). In addition to the applicable Consideration, holders of Notes validly tendered and not validly withdrawn at
or before the Expiration Time and accepted for purchase will also be paid accrued and unpaid interest from the last interest payment date for such Notes to, but not including, the Settlement Date (as defined below) (&#147;<B>Accrued
Interest</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Consideration and Accrued Interest will be paid on the settlement date (the &#147;<B>Settlement Date</B>&#148;),
which is expected to be May&nbsp;10, 2022. The Company&#146;s obligations to accept for purchase, and to pay for, Notes validly tendered and not validly withdrawn pursuant to the Offer is subject to, and conditioned upon, the satisfaction of or,
where available, the Company&#146;s waiver of, the conditions set forth in the Offer to Purchase, including the successful completion (in the sole discretion of the Company) of the New Euro Notes Issuance (the &#147;<B>Financing
Condition</B>&#148;). See &#147;The Offer&#151;Conditions to the Offer&#151;Financing Condition&#148; in the Offer to Purchase for further details. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth the Reference Yield, Fixed Spread and the applicable Consideration for each series
of Notes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title of Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security&nbsp;Identifier(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference&nbsp;U.S.<BR>Treasury&nbsp;Security</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reference&nbsp;Yield</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fixed&nbsp;Spread</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Consideration&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7<SUP STYLE="font-size:85%; vertical-align:top">1/8</SUP>% Series A Debentures due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>CUSIP</U>:&nbsp;718337AB4 <U>ISIN</U>:&nbsp;US718337AB40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">84,169,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.625%&nbsp;U.S.&nbsp;Treasury due April&nbsp;15, 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.892</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70&nbsp;bps</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,100.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7<SUP STYLE="font-size:85%; vertical-align:top">3/4</SUP>% Series B Debentures due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>CUSIP</U>: 718337AC2</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>ISIN</U>:
US718337AC23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">63,285,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.625% U.S. Treasury due April&nbsp;15, 2025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.892</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70 bps</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,117.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.200% Notes due 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>CUSIP</U>: 718337AE8</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>ISIN</U>:
US718337AE88</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">136,515,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.50% U.S. Treasury due March&nbsp;31, 2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.002</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75 bps</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,128.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per $1,000 principal amount of Notes accepted for purchase by the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release is qualified in its entirety by the Offer to Purchase and the related Notice of Guaranteed Delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has retained BofA Securities Europe SA and Mizuho Securities USA LLC as Dealer Managers in connection with the Offer. Kroll Issuer Services
Limited is the Tender and Information Agent (the &#147;<B>Tender and Information Agent</B>&#148;). For additional information regarding the terms of the Offer, please contact: BofA Securities by telephone at +1 (980)
<FONT STYLE="white-space:nowrap">387-3907</FONT> (US), +1 (888) <FONT STYLE="white-space:nowrap">292-0070</FONT> (U.S. Toll Free) or +33 1 877 01057 (Europe) or by email at <FONT STYLE="white-space:nowrap">DG.LM-EMEA@bofa.com</FONT> or Mizuho
Securities by telephone at +1 212 <FONT STYLE="white-space:nowrap">205-7736</FONT> (Collect), +1 866 <FONT STYLE="white-space:nowrap">271-7403</FONT> (U.S. Toll Free) or +44 20 7090 6134 (In London) or by email at
<FONT STYLE="white-space:nowrap">LiabilityManagement@uk.mizuho-sc.com.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any questions or requests for assistance or for additional copies of the
Offer to Purchase or the Notice of Guaranteed Delivery and any amendments or supplements to the foregoing may be directed to the Tender and Information Agent by telephone at +44 20 7704 0880 or by email at philips@is.kroll.com, or to any of the
Dealer Managers at their respective telephone numbers or email addresses above. These documents regarding the Offer are also available at https://deals.is.kroll.com/philips. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information, please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ben Zwirs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philips Global Press Office </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: +31 6 1521 3446 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> ben.zwirs@philips.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derya Guzel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philips Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: +31 20 5977055 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> derya.guzel@philips.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Royal Philips </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving people&#146;s health and well-being, and enabling better outcomes across the health continuum &#150; from healthy living and prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics,
as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2&nbsp;billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at
www.philips.com/newscenter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains certain &#147;forward-looking statements&#148; with respect to the Company. Forward-looking statements can be identified generally as
those containing words such as &#147;anticipates&#148;, &#147;assumes&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;expects&#148;, &#147;should&#148;, &#147;will&#148;, &#147;will likely result&#148;, &#147;forecast&#148;,
&#147;outlook&#148;, &#147;projects&#148;, &#147;may&#148; or similar expressions. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events that depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: the Company&#146;s ability to
gain leadership in health informatics in response to developments in the health technology industry; the Company&#146;s ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; the
Company&#146;s integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining the Company&#146;s intellectual property rights, and unauthorized use of third-party intellectual property
rights; ability to meet expectations with respect to <FONT STYLE="white-space:nowrap">ESG-related</FONT> matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations;
breach of cybersecurity; ability to execute and deliver on programs on business transformation and IT system changes and continuity; the effectiveness of the Company&#146;s supply chain; attracting and retaining personnel; <FONT
STYLE="white-space:nowrap">COVID-19</FONT> and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security;
compliance with business conduct rules and regulations; treasury and financing risks; tax risks; and reliability of internal controls, financial reporting and management process. As a result, the Company&#146;s actual future results may differ
materially from the plans, goals and expectations set forth in such forward-looking statements. In view of such uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. See &#147;9.2 Risk factors&#148; in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2021 for a discussion of certain risks relating to the business of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release shall not constitute
an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. The Offer is being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. The distribution of the Offer
to Purchase in certain jurisdictions may be restricted by law. Persons who come into possession of the Offer to Purchase or any related documents are required by each of the Company, the Dealer Managers and the Tender and Information Agent to inform
themselves about and to observe any such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer to Purchase and the related Notice of Guaranteed Delivery contain important information
that holders are urged to read carefully before making any decision with respect to the Offer. None of the Company, its statutory board, executive committee or supervisory board, the Tender and Information Agent, any of the Dealer Managers or any
trustee for the Notes is making any recommendation as to whether holders should tender all or any portion of their Notes in response to the Offer. Holders must make their own decisions as to whether to tender, or refrain from tendering, their Notes,
and the principal amount of Notes to tender, if any. Holders should consult their tax, accounting, financial and legal advisers regarding the tax, accounting, financial and legal consequences of participating or refraining from participating in the
Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The communication of the Offer to Purchase and any other documents or materials relating to the Offer is not being made, and such documents and/or materials
have not been approved, by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, the Offer to Purchase and such documents and/or materials are not being distributed to, and must
not be passed on to, the general public in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United Kingdom. The communication of the Offer to Purchase and such documents and/or materials as a financial promotion is only being directed at and made to (i)&nbsp;those persons in the United
Kingdom falling within the definition of &#147;<B>investment professionals</B>&#148; (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;<B>Financial Promotion
Order</B>&#148;)), (ii) those persons who are existing members or creditors of the Company and other persons falling within Article 43(2) of the Financial Promotion Order, (iii)&nbsp;persons who are outside the United Kingdom and (iv)&nbsp;any other
persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as &#147;<B>relevant persons</B>&#148;). Any person in the United Kingdom who is not a relevant person should not act or rely on the Offer to
Purchase or such documents and/or materials or any of their content. Any investment or investment activity to which the Offer to Purchase or such other documents or materials relate is available only to and will be engaged in only with relevant
persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Belgium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Offer to Purchase nor
any other documents or materials relating to the Offer have been submitted to or will be submitted for approval or recognition to the Financial Services and Markets Authority (<I>Autorit&eacute; des services et march&eacute;s financiers/Autoriteit
voor financi&euml;le diensten en markten</I>) and, accordingly, the Offer may not be made in Belgium by way of a public offering, as defined in Articles 3 and 6 of the Belgian Law of April&nbsp;1, 2007 on public takeover bids as amended or replaced
from time to time. Accordingly, the Offer may not be advertised and the Offer will not be extended, and neither the Offer to Purchase nor any other documents or materials relating to the Offer (including any memorandum, information circular,
brochure or any similar documents) has been or shall be distributed or made available, directly or indirectly, to any person in Belgium other than a &#147;<B>qualified investor</B>&#148; (<I>investisseur qualifi&eacute;/gekwalificeerde belegger</I>)
as defined in Article 10 of the Belgian Law of June&nbsp;16, 2006 on the public offer of placement instruments and the admission to trading of placement instruments on regulated markets, acting for its own account. The Offer to Purchase has been
issued only for the personal use of the above qualified investors and exclusively for the purpose of the Offer. Accordingly, the information contained in the Offer to Purchase may not be used for any other purpose or disclosed to any other person in
Belgium. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>France </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer is not being made,
directly or indirectly, to the public in France. Neither the Offer to Purchase nor any other documents or offering materials relating to the Offer, has been or shall be distributed to the public in France and only (i)&nbsp;providers of investment
services relating to portfolio management for the account of third parties (<I>personnes fournissant le service d&#146;investissement de gestion de portefeuille pour compte de tiers</I>) and/or (ii)&nbsp;qualified investors (<I>investisseurs
qualifi&eacute;s</I>), other than individuals, acting for their own account, all as defined in, and in accordance with, Articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT
STYLE="white-space:nowrap">D.411-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code <I>mon&eacute;taire et financier</I>,
are eligible to participate in the Offer. The Offer to Purchase has not been and will not be submitted for clearance procedures (visa) of the <I>Autorit&eacute; des march&eacute;s financiers</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Italy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the Offer, the Offer to Purchase or any
other documents or materials relating to the Offer has been or will be submitted to the clearance procedure of the <I>Commissione Nazionale per le Societ&agrave; e la Borsa</I> (&#147;<B>CONSOB</B>&#148;), pursuant to applicable Italian laws and
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer is being carried out in Italy as an exempted offer pursuant to article <FONT STYLE="white-space:nowrap">101-bis,</FONT> paragraph <FONT
STYLE="white-space:nowrap">3-bis</FONT> of the Legislative Decree No.&nbsp;58 of February&nbsp;24, 1998, as amended (the &#147;<B>Financial Services Act</B>&#148;) and article <FONT STYLE="white-space:nowrap">35-bis,</FONT> paragraph 4 of CONSOB
Regulation No.&nbsp;11971 of May&nbsp;14, 1999, as amended (the &#147;<B>CONSOB Regulation</B>&#148;). The Offer is also being carried out in compliance with article <FONT STYLE="white-space:nowrap">35-bis,</FONT> paragraph 7 of the CONSOB
Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders or beneficial owners of the Notes located in Italy can tender the Notes through authorized persons
(such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No.&nbsp;16190 of October&nbsp;29, 2007, as amended from time to time, and
Legislative Decree No.&nbsp;385 of September&nbsp;1, 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each intermediary must comply with the applicable laws and regulations concerning information duties <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> its clients in connection with the Notes or the Offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Netherlands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Netherlands, the Offer will not, directly or indirectly, be made to, or for the account of, any person other than to qualified investors as referred to
in the Prospectus Regulation. Neither the Offer to Purchase nor any other documentation or material relating to the Offer has been or will submitted to the Dutch Authority for Financial Markets (<I>de Autoriteit Financi&euml;le Markten, </I>the
&#147;<B>AFM</B>&#148;) for approval. Therefore, neither the Offer to Purchase nor any documentation or material relating to the Offer qualify as an approved prospectus as meant in the Prospectus Regulation. Accordingly, in the Netherlands, the
Offer may not be made by way of a public offer within the meaning of the Prospectus Regulation and the Offer may not be promoted and is not being made to, any person in the Netherlands (with the exception of &#147;<B>qualified investors</B>&#148;
within the meaning of the Prospectus Regulation). The Offer to Purchase and any other documentation or material relating to the Offer (including memoranda, information circulars, brochures or similar documents) have not been forwarded or made
available to, and are not being forwarded or made available to, directly or indirectly, any such person. With regard to the Netherlands, the Offer to Purchase has been transmitted only for personal use by the aforementioned qualified investors and
only for the purpose of the Offer. Accordingly, the information contained in the Offer to Purchase may not be used for any other purpose or be transmitted to any other person in the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d322054dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN, ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR
DISTRIBUTION IS UNLAWFUL </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May&nbsp;6, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Koninklijke Philips N.V. Announces Tender Results of Any and All Tender Offer for Certain Outstanding
<FONT STYLE="white-space:nowrap">USD-Denominated</FONT> Notes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amsterdam, The Netherlands </B>&#150; Koninklijke Philips N.V. (&#147;<B>Royal
Philips</B>&#148; or the &#147;<B>Company</B>&#148;) today announces that, pursuant to its previously announced tender offer (the &#147;<B>Offer</B>&#148;) to purchase for cash any and all of its outstanding 7<SUP
STYLE="font-size:85%; vertical-align:top">1/8</SUP>% Series A Debentures due 2025 (the &#147;<B>2025 Series A Notes</B>&#148;), 7<SUP STYLE="font-size:85%; vertical-align:top">3/4</SUP>% Series B Debentures due 2025 (the &#147;<B>2025 Series B
Notes</B>&#148;) and 7.200% Notes due 2026 (the &#147;<B>2026 Notes</B>&#148; and, together with the 2025 Series A Notes and the 2025 Series B Notes, the &#147;<B>Notes</B>&#148;), approximately $20,862,000 in aggregate principal amount of Notes was
validly tendered and not validly withdrawn at or before 5:00 p.m., New York City time, on May&nbsp;5, 2022, the expiration time for the Offer (the &#147;<B>Expiration Time</B>&#148;). No Notes were tendered pursuant to the Guaranteed Delivery
Procedures. The Offer is being made in accordance with the terms and subject to the conditions set forth in the Offer to Purchase, dated April&nbsp;28, 2022 (the &#147;<B>Offer to Purchase</B>&#148;) and the related Notice of Guaranteed Delivery.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final deadline to withdraw tendered Notes was 5:00 p.m., New York City time, on May&nbsp;5, 2022 and, as a result, tendered Notes may no longer be
withdrawn, except in certain limited circumstances where additional withdrawal rights are required by law (as determined by the Company). Holders of Notes validly tendered and not validly withdrawn at or before the Expiration Time and accepted for
purchase will receive the Consideration (as defined below) for such Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable &#147;<B>Consideration</B>&#148; for Notes accepted for
purchase pursuant to the Offer was determined and announced on May&nbsp;5, 2022. Settlement of the New Euro Notes Issuance took place on May&nbsp;5, 2022 and accordingly the Financing Condition has been satisfied. In addition to the Consideration,
holders of Notes validly tendered and not validly withdrawn at or before the Expiration Time and accepted for purchase will also be paid accrued and unpaid interest from the last interest payment date for such Notes to, but not including, the
Settlement Date (as defined below) (&#147;<B>Accrued Interest</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable Consideration and Accrued Interest will be paid on the
settlement date (the &#147;<B>Settlement Date</B>&#148;), which is expected to be May&nbsp;10, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth the aggregate principal
amount of each series of Notes validly tendered and not validly withdrawn at or before the Expiration Time, the applicable Consideration and the total principal amount of Notes of each series that the Company expects to remain outstanding after the
Settlement Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title of Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Security Identifier(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount<BR>Tendered as<BR>of the<BR>Expiration<BR>Time<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount<BR>Outstanding<BR>after Settlement<BR>Date<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Consideration<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7<SUP STYLE="font-size:85%; vertical-align:top">1/8</SUP>% Series A Debentures due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>CUSIP</U>:&nbsp;718337AB4 <U>ISIN</U>:&nbsp;US718337AB40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,535,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,634,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,100.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7<SUP STYLE="font-size:85%; vertical-align:top">3/4</SUP>% Series B Debentures due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>CUSIP</U>: 718337AC2 <U>ISIN</U>:&nbsp;US718337AC23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,143,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,142,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,117.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.200% Notes due 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>CUSIP</U>: 718337AE8 <U>ISIN</U>:&nbsp;US718337AE88</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,184,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,128.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Notes were tendered pursuant to the Guaranteed Delivery Procedures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per $1,000 principal amount of Notes accepted for purchase by the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release is qualified in its entirety by the Offer to Purchase and the related Notice of Guaranteed Delivery. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has retained BofA Securities Europe SA and Mizuho Securities USA LLC as Dealer Managers in
connection with the Offer. Kroll Issuer Services Limited is the Tender and Information Agent (the &#147;<B>Tender and Information Agent</B>&#148;). For additional information regarding the terms of the Offer, please contact: BofA Securities by
telephone at +1 (980) <FONT STYLE="white-space:nowrap">387-3907</FONT> (US), +1 (888) <FONT STYLE="white-space:nowrap">292-0070</FONT> (U.S. Toll Free) or +33 1 877 01057 (Europe) or by email at
<FONT STYLE="white-space:nowrap">DG.LM-EMEA@bofa.com</FONT> or Mizuho Securities by telephone at +1 212 <FONT STYLE="white-space:nowrap">205-7736</FONT> (Collect), +1 866 <FONT STYLE="white-space:nowrap">271-7403</FONT> (U.S. Toll Free) or +44 20
7090 6134 (In London) or by email at <FONT STYLE="white-space:nowrap">LiabilityManagement@uk.mizuho-sc.com.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any questions or requests for
assistance or for additional copies of the Offer to Purchase or the Notice of Guaranteed Delivery and any amendments or supplements to the foregoing may be directed to the Tender and Information Agent by telephone at +44 20 7704 0880 or by email at
philips@is.kroll.com, or to any of the Dealer Managers at their respective telephone numbers or email addresses above. These documents regarding the Offer are also available at https://deals.is.kroll.com/philips. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information, please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ben Zwirs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philips Global Press Office </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: +31 6 1521 3446 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> ben.zwirs@philips.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derya Guzel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philips Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: +31 20 5977055 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> derya.guzel@philips.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Royal Philips </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving people&#146;s health and well-being, and enabling better outcomes across the health continuum &#150; from healthy living and prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics,
as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2&nbsp;billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at
www.philips.com/newscenter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains certain &#147;forward-looking statements&#148; with respect to the Company. Forward-looking statements can be identified generally as
those containing words such as &#147;anticipates&#148;, &#147;assumes&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;expects&#148;, &#147;should&#148;, &#147;will&#148;, &#147;will likely result&#148;, &#147;forecast&#148;,
&#147;outlook&#148;, &#147;projects&#148;, &#147;may&#148; or similar expressions. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events that depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: the Company&#146;s ability to
gain leadership in health informatics in response to developments in the health technology industry; the Company&#146;s ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; the
Company&#146;s integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining the Company&#146;s intellectual property rights, and unauthorized use of third-party intellectual property
rights; ability to meet expectations with respect to <FONT STYLE="white-space:nowrap">ESG-related</FONT> matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations;
breach of cybersecurity; ability to execute and deliver on programs on business transformation and IT system changes and continuity; the effectiveness of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#146;s supply chain; attracting and retaining personnel;
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber)
security; compliance with business conduct rules and regulations; treasury and financing risks; tax risks; and reliability of internal controls, financial reporting and management process. As a result, the Company&#146;s actual future results may
differ materially from the plans, goals and expectations set forth in such forward-looking statements. In view of such uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. See &#147;9.2 Risk factors&#148; in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2021 for a discussion of certain risks relating to the business of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release shall not constitute
an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. The Offer is being made only pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. The distribution of the Offer
to Purchase in certain jurisdictions may be restricted by law. Persons who come into possession of the Offer to Purchase or any related documents are required by each of the Company, the Dealer Managers and the Tender and Information Agent to inform
themselves about and to observe any such restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer to Purchase and the related Notice of Guaranteed Delivery contain important information
that holders are urged to read carefully before making any decision with respect to the Offer. None of the Company, its statutory board, executive committee or supervisory board, the Tender and Information Agent, any of the Dealer Managers or any
trustee for the Notes is making any recommendation as to whether holders should tender all or any portion of their Notes in response to the Offer. Holders must make their own decisions as to whether to tender, or refrain from tendering, their Notes,
and the principal amount of Notes to tender, if any. Holders should consult their tax, accounting, financial and legal advisers regarding the tax, accounting, financial and legal consequences of participating or refraining from participating in the
Offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The communication of the Offer to Purchase and any other documents or materials relating to the Offer is not being made, and such documents and/or materials
have not been approved, by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, the Offer to Purchase and such documents and/or materials are not being distributed to, and must
not be passed on to, the general public in the United Kingdom. The communication of the Offer to Purchase and such documents and/or materials as a financial promotion is only being directed at and made to (i)&nbsp;those persons in the United Kingdom
falling within the definition of &#147;<B>investment professionals</B>&#148; (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;<B>Financial Promotion
Order</B>&#148;)), (ii) those persons who are existing members or creditors of the Company and other persons falling within Article 43(2) of the Financial Promotion Order, (iii)&nbsp;persons who are outside the United Kingdom and (iv)&nbsp;any other
persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as &#147;<B>relevant persons</B>&#148;). Any person in the United Kingdom who is not a relevant person should not act or rely on the Offer to
Purchase or such documents and/or materials or any of their content. Any investment or investment activity to which the Offer to Purchase or such other documents or materials relate is available only to and will be engaged in only with relevant
persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Belgium </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the Offer to Purchase nor any other documents or materials relating to the Offer have been submitted to or will be submitted for approval or
recognition to the Financial Services and Markets Authority (<I>Autorit&eacute; des services et march&eacute;s financiers/Autoriteit voor financi&euml;le diensten en markten</I>) and, accordingly, the Offer may not be made in Belgium by way of a
public offering, as defined in Articles 3 and 6 of the Belgian Law of April&nbsp;1, 2007 on public takeover bids as amended or replaced from time to time. Accordingly, the Offer may not be advertised and the Offer will not be extended, and neither
the Offer to Purchase nor any other documents or materials relating to the Offer (including any memorandum, information circular, brochure or any similar documents) has been or shall be distributed or made available, directly or indirectly, to any
person in Belgium other than a &#147;<B>qualified investor</B>&#148; (<I>investisseur qualifi&eacute;/gekwalificeerde belegger</I>) as defined in Article 10 of the Belgian Law of June&nbsp;16, 2006 on the public offer of placement instruments and
the admission to trading of placement instruments on regulated markets, acting for its own account. The Offer to Purchase has been issued only for the personal use of the above qualified investors and exclusively for the purpose of the Offer.
Accordingly, the information contained in the Offer to Purchase may not be used for any other purpose or disclosed to any other person in Belgium. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>France </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer is not being made, directly or
indirectly, to the public in France. Neither the Offer to Purchase nor any other documents or offering materials relating to the Offer, has been or shall be distributed to the public in France and only (i)&nbsp;providers of investment services
relating to portfolio management for the account of third parties (<I>personnes fournissant le service d&#146;investissement de gestion de portefeuille pour compte de tiers</I>) and/or (ii)&nbsp;qualified investors (<I>investisseurs
qualifi&eacute;s</I>), other than individuals, acting for their own account, all as defined in, and in accordance with, Articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT
STYLE="white-space:nowrap">D.411-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code <I>mon&eacute;taire et financier</I>,
are eligible to participate in the Offer. The Offer to Purchase has not been and will not be submitted for clearance procedures (visa) of the <I>Autorit&eacute; des march&eacute;s financiers</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Italy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the Offer, the Offer to Purchase or any
other documents or materials relating to the Offer has been or will be submitted to the clearance procedure of the <I>Commissione Nazionale per le Societ&agrave; e la Borsa</I> (&#147;<B>CONSOB</B>&#148;), pursuant to applicable Italian laws and
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offer is being carried out in Italy as an exempted offer pursuant to article <FONT STYLE="white-space:nowrap">101-bis,</FONT> paragraph <FONT
STYLE="white-space:nowrap">3-bis</FONT> of the Legislative Decree No.&nbsp;58 of February&nbsp;24, 1998, as amended (the &#147;<B>Financial Services Act</B>&#148;) and article <FONT STYLE="white-space:nowrap">35-bis,</FONT> paragraph 4 of CONSOB
Regulation No.&nbsp;11971 of May&nbsp;14, 1999, as amended (the &#147;<B>CONSOB</B> <B>Regulation</B>&#148;). The Offer is also being carried out in compliance with article <FONT STYLE="white-space:nowrap">35-bis,</FONT> paragraph 7 of the CONSOB
Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders or beneficial owners of the Notes located in Italy can tender the Notes through authorized persons (such as investment firms, banks
or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No.&nbsp;16190 of October&nbsp;29, 2007, as amended from time to time, and Legislative Decree No.&nbsp;385 of
September&nbsp;1, 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each intermediary must comply with the applicable laws and regulations concerning information duties <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> its clients in connection with the Notes or the Offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Netherlands </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Netherlands, the Offer will not, directly or indirectly, be made to, or for the account of, any person other than to qualified investors as referred to
in the Prospectus Regulation. Neither the Offer to Purchase nor any other documentation or material relating to the Offer has been or will submitted to the Dutch Authority for Financial Markets (<I>de Autoriteit Financi&euml;le Markten, </I>the
&#147;<B>AFM</B>&#148;) for approval. Therefore, neither the Offer to Purchase nor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON RESIDENT AND/OR LOCATED IN,
ANY JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g322054dsp10.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any documentation or material relating to the Offer qualify as an approved prospectus as meant in the Prospectus Regulation. Accordingly, in the Netherlands, the Offer may not be made by way of a
public offer within the meaning of the Prospectus Regulation and the Offer may not be promoted and is not being made to, any person in the Netherlands (with the exception of &#147;<B>qualified investors</B>&#148; within the meaning of the Prospectus
Regulation). The Offer to Purchase and any other documentation or material relating to the Offer (including memoranda, information circulars, brochures or similar documents) have not been forwarded or made available to, and are not being forwarded
or made available to, directly or indirectly, any such person. With regard to the Netherlands, the Offer to Purchase has been transmitted only for personal use by the aforementioned qualified investors and only for the purpose of the Offer.
Accordingly, the information contained in the Offer to Purchase may not be used for any other purpose or be transmitted to any other person in the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g322054dsp10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g322054dsp10.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MLSTH5(U%>#N7JR+.,^*7_(CW'_76/_T*O4RK_>5\SBQW\!_(\&KZX^>._O\
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MK3Y9)6/-_&G_ ".FK_\ 7PU>Y@?]VAZ'F8O^-([CX+_\QO\ [8?^U*\G._\
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MS9U)U)<TW=G9&,8*T58LU!04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
4% !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
